American Herbal Products Association (AHPA) > News

AHPA represents member interests at Cosmetic Ingredient Review meeting

AHPA attends Cosmetic Ingredient Review meeting finalizing Ginkgo biloba and eucalyptus cosmetic ingredient safety reports

American Herbal Products Association (AHPA) Chief Information Analyst Merle Zimmermann, Ph.D., attended the 147th Cosmetic Ingredient Review (CIR) Expert Panel Meeting on the safety of ingredients used in cosmetics held in Washington, D.C., Jun. 4-5. The meeting included discussions of two CIR safety reports being developed on Gingko biloba and eucalyptus cosmetic ingredients.

AHPA Presents at Canna West 2018

AHPA Chief Science Officer Dr. Johnson highlights AHPA resources for the cannabis industry

AHPA Chief Science Officer Holly Johnson, Ph.D., participated in a panel discussion yesterday on testing and labeling standards for cannabis products to increase product safety and decrease producers’ liability at Canna West 2018 held in Los Angeles.

AHPA recommends oshá harvest permitting in GMUG National Forests

Research supported by the AHPA ERB Foundation concludes plants have a high capacity for post‐harvest recolonization

AHPA recently submitted comments to the Grand Mesa, Uncompahgre and Gunnison (GMUG) National Forests to recommend that a revision of its plan for land and resource management include a process for permitting commercial harvest of oshá (Ligusticum porteri) root.

A Primer on AHPA’s Good Agricultural and Collection Practices and Good Manufacturing Practices (GACP-GMP) Guidance for Botanical Materials

What is AHPA's GACP-GMP guidance and how can it help your business?

Recorded May 22, 2018 -- Member cost: $150. Nonmember cost: $350.

AHPA endorses the Hemp Farming Act of 2018

AHPA Board adopts policy to support any state or federal efforts to decriminalize hemp

AHPA is endorsing federal legislation recently introduced to decriminalize hemp and the AHPA Board of Trustees has adopted a policy for the association to support any future state or federal legislation to decriminalize the plant and all its derivatives.

IADSA update on international supplement regulations

IADSA April 2018 Newsflash

This issue of the IADSA Newsflash includes an update on EFSA's proposed limit of 800 mg/day for the intake of green tea catechins in food supplements

AHPA President Michael McGuffin urges companies selling kratom to comply with all applicable laws and regulations

Statement delivered during press conference

AHPA President Michael McGuffin stressed that any company looking to sell kratom or kratom products must comply with all applicable laws and regulations during a press conference.

AHPA recommends CBD not be scheduled under any international drug control convention

AHPA submits comments to FDA to inform participation in WHO Expert Committee on Drug Dependence

AHPA submitted comments to the Food and Drug Administration (FDA) yesterday to stress that cannabidiol (CBD) requires no international drug scheduling as an individual substance and encourage the U.S. to support this position.

Rate of NDI notifications reported by FDA unexpectedly drops

More than half of most recent NDI notifications available from FDA filed without comment

More than half of the most recent new dietary ingredient (NDI) notifications provided by the Food and Drug Administration (FDA) in the last six months were filed without comment, but the rate of notifications reported received by the agency is dramatically lower than previously observed for any six month period since the initial six months in 1995 when the agency first began accepting and filing notifications.

AHPA supports FDA Guidance making pure or highly concentrated caffeine dietary supplements unlawful

AHPA policy prohibits the sale of pure caffeine

FDA issued guidance titled, "Highly Concentrated Caffeine in Dietary Supplements: Guidance for Industry," to explain that it generally considers pure or highly concentrated caffeine dietary supplements, sold in bulk directly to consumers, to be adulterated because they present a significant or unreasonable risk of illness or injury. The principle in this guidance is consistent with a policy adopted by AHPA members in 2015.

Alerts

Subscribe>>

AHPA Alerts

Subscribe >>

Recent News